Neurotech international is a company researching cannabis for the treatment of neurological conditions such as autism, multiple sclerosis and epilepsy. They are working on NTI164, the world’s first full-spectrum medicinal cannabis product, for children with autism.
By combining cannabinoids in NTI164 and not just using CBD, there is a powerful effect on inflammatory pathways as well as suppressing cytokine activity. By working with different pathways than CBD, the issue can be solved from several angles. The company has identified three active pathways which are involved in cell health, cell survival and cell maintenance.
Clinical Trials: Yes
NEWS & PARTNERSHIPS:
2021
The company secured a strategic cultivation partnership with CannaPacific for the growth of NTI’s Dolce medicinal cannabis. The partnership will o assist in the development of varietal elite strains developed by Dolce Cann through their exclusive licencing agreement with NTI.
The company expanded its exclusive licensing with Dolce Cann Global to include all neurological disorders.
2022
The company announced the receipt of a 1.189 million AUD R&D Tax Incentive rebate for the year.
2023
The company received a 3.17 million AUD research and development tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme for the year.
2024
The company announced a strategic partnership with Fenix Innovation Group for the exclusive cooperation in the medicinal cannabis field with the development of the NTI’s broad spectrum cannabinoid drug therapy NTI164 for neurological disorders.
The FDA granted the company orphan drug designation for the use of NTI164 in children and adults diagnosed with Rett Syndrome.
The company received a $2.44 Million R&D tax incentive refund under the Australian Federal Government’s R&D tax incentive scheme
2025
The company entered into a partnership agreement with RH Farma in Macedonia, a subisidary of European Cannabis Company, for the creation of a strain-agnostic, pharmaceutical-grade broad spectrum cannabinoid drug product suitable for paediatric patients with neurodevelopmental disorders and is based on RH Pharma’s proprietary CO2 extraction technology.
The European Commission granted NTI164 an orphan drug designation for Rett Syndrome.